European Society for Medical Oncology Congress (ESMO)

Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.

Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.

Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.

Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.

Subgroup analyses in the phase 3 KEYNOTE-641 trial do not indicate an overall survival improvement with pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer.

Those with advanced mucosal melanoma who were treated with lifileucel saw clinically meaningful activity.

Belzutifan vs everolimus saw increased progression-free survival and objective response rate in patients with pretreated advanced clear cell renal cell carcinoma.

Results from the phase 1b/2 ACTIVATE trial showed tolerability among the combination of etigilimab plus nivolumab in patients with recurrent or advanced solid tumors.

Selpercatinib significantly improved efficacy in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer.

Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.

Patients with RET fusion–positive non–small cell lung cancer experienced improved progression-free survival with first-line selpercatinib.

Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.

Central nervous system progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

Shannon N. Westin, MD, MPH, FACOG, presented results showing a progression-free survival response with combination durvalumab plus olaparib in newly diagnosed advanced or recurrent endometrial cancer.

Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.

Results presented at 2023 ESMO showed a prolonged survival benefit in patients receiving adjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma.

Belzutifan plus cabozantinib showed continued anti-tumor activity in patients with clear cell renal cell carcinoma.

Results from an updated analysis of the DESTINY-Breast04 trial indicate an efficacy improvement when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.

Central nervous system progression-free survival appears to be longer with trastuzumab deruxtecan than with comparator treatment in those with HER2-positive metastatic breast cancer and brain metastases.

Atezolizumab plus platinum chemotherapy showed significant improvement in progression-free survival for patients with frontline advanced or recurrent endometrial carcinoma.

Sacituzumab govitecan showed anti-tumor activity in patients with pretreated metastatic or locally recurrent head and neck squamous cell carcinoma.

Patients with recurrent ovarian cancer did not see an improvement in efficacy when given atezolizumab plus chemotherapy and niraparib.

The phase 3 KEYNOTE-756 trial yielded an increased pathological complete response for those with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer receiving pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy.

Pembrolizumab combination yielded an improved progression-free survival benefit vs placebo in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Pembrolizumab appears to improve overall survival vs placebo when added to trastuzumab and chemotherapy among patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Findings from the ENZA-p study provide evidence for enhanced anti-cancer effects with 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.

Data from the phase 2 KRYSTAL-7 study support a phase 3 trial assessing concurrent adagrasib plus pembrolizumab compared with pembrolizumab alone in treatment-naïve KRAS G12C-mutated non–small cell lung cancer.

Adding durvalumab to standard-of-care chemotherapy appears to improve downstaging in patients with resectable gastric cancer and gastroesophageal junction cancer in the phase 3 MATTERHORN study.